These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 37813601)

  • 1. Independent Link Between Use of Mineralocorticoid Receptor Antagonists and Muscle Wasting in Heart Failure Patients Not Receiving Renin-Angiotensin System Inhibitors.
    Numazawa R; Katano S; Yano T; Nagaoka R; Ohori K; Kouzu H; Honma S; Fujisawa Y; Yamano K; Osanami A; Koyama M; Hashimoto A; Furuhashi M
    Circ J; 2023 Dec; 88(1):10-19. PubMed ID: 37813601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does renin-angiotensin system inhibition have impacts on muscle mass and bone mineral density in heart failure patients?
    Katano S; Yano T; Shimizu M; Ohori K; Kouzu H; Koyama M; Nagaoka R; Inoue T; Takamura Y; Ishigo T; Takashima H; Katayose M; Ohnishi H; Miura T
    ESC Heart Fail; 2021 Aug; 8(4):2617-2624. PubMed ID: 34002947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct determinants of muscle wasting in nonobese heart failure patients with and without type 2 diabetes mellitus.
    Yano T; Katano S; Kouzu H; Nagaoka R; Inoue T; Takamura Y; Ishigo T; Watanabe A; Ohori K; Koyama M; Nagano N; Fujito T; Nishikawa R; Hashimoto A; Miura T
    J Diabetes; 2021 Jan; 13(1):7-18. PubMed ID: 32677311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality.
    Beusekamp JC; Tromp J; Cleland JGF; Givertz MM; Metra M; O'Connor CM; Teerlink JR; Ponikowski P; Ouwerkerk W; van Veldhuisen DJ; Voors AA; van der Meer P
    JACC Heart Fail; 2019 Nov; 7(11):970-979. PubMed ID: 31606364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex differences in heart failure medications targeting the renin-angiotensin-aldosterone system.
    Nicolaou PA
    Eur J Pharmacol; 2021 Apr; 897():173961. PubMed ID: 33617824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
    Martin N; Manoharan K; Davies C; Lumbers RT
    Cochrane Database Syst Rev; 2021 May; 5(5):CD012721. PubMed ID: 34022072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma renin activity is a strong and independent prognostic indicator in patients with acute decompensated heart failure treated with renin-angiotensin system inhibitors.
    Ueda T; Kawakami R; Nishida T; Onoue K; Soeda T; Okayama S; Takeda Y; Watanabe M; Kawata H; Uemura S; Saito Y
    Circ J; 2015; 79(6):1307-14. PubMed ID: 25753468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment Persistence of Renin-Angiotensin-Aldosterone-System Inhibitors Over Time in Heart Failure with Reduced Ejection Fraction.
    Vaduganathan M; Fonarow GC; Greene SJ; Devore AD; Albert NM; Duffy CI; Hill CL; Patterson JH; Spertus JA; Thomas LE; Williams FB; Hernandez AF; Butler J
    J Card Fail; 2022 Feb; 28(2):191-201. PubMed ID: 34428591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
    Yang S; Zhao L; Mi Y; He W
    Diabetes Obes Metab; 2022 Nov; 24(11):2159-2168. PubMed ID: 35712807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.
    Desai AS; Vardeny O; Claggett B; McMurray JJ; Packer M; Swedberg K; Rouleau JL; Zile MR; Lefkowitz M; Shi V; Solomon SD
    JAMA Cardiol; 2017 Jan; 2(1):79-85. PubMed ID: 27842179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
    Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study.
    Pitt B; Latini R; Maggioni AP; Solomon SD; Smith BA; Wright M; Prescott MF; McMurray JJ
    Eur J Heart Fail; 2011 Jul; 13(7):755-64. PubMed ID: 21467028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contemporary Drug Treatment of Chronic Heart Failure With Reduced Ejection Fraction: The CHECK-HF Registry.
    Brunner-La Rocca HP; Linssen GC; Smeele FJ; van Drimmelen AA; Schaafsma HJ; Westendorp PH; Rademaker PC; van de Kamp HJ; Hoes AW; Brugts JJ;
    JACC Heart Fail; 2019 Jan; 7(1):13-21. PubMed ID: 30606482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blockade of Renin-Angiotensin-Aldosterone System in Elderly Patients with Heart Failure and Chronic Kidney Disease: Results of a Single-Center, Observational Cohort Study.
    Martínez-Milla J; García MC; Urquía MT; Castillo ML; Arbiol AD; Monteagudo ALR; Mariscal MLM; Figuero SB; Franco-Pelaéz JA; Tuñón J
    Drugs Aging; 2019 Dec; 36(12):1123-1131. PubMed ID: 31493202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits and Risks of Continuing Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Antagonists, and Mineralocorticoid Receptor Antagonists during Hospitalizations for Acute Heart Failure.
    Oliveros E; Oni ET; Shahzad A; Kluger AY; Lo KB; Rangaswami J; McCullough PA
    Cardiorenal Med; 2020; 10(2):69-84. PubMed ID: 32062648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New approaches to blockade of the renin-angiotensin-aldosterone system: mineralocorticoid-receptor blockers exert antihypertensive and renoprotective effects independently of the renin-angiotensin system.
    Nishiyama A; Hasegawa K; Diah S; Hitomi H
    J Pharmacol Sci; 2010; 113(4):310-4. PubMed ID: 20675957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "Renalism" with Renin Angiotensin Aldosterone System Inhibitor Use in Patients Enrolled in Trials for Heart Failure with Reduced Ejection Fraction and Advanced Chronic Kidney Disease: A Systematic Review.
    Sudani HA; Shah S; Lo KB; Essa H; Wattoo A; Angelim L; Brousas S; Whybrow-Huppatz I; Vellanki S; Sankaranarayanan R; Rangaswami J
    Curr Vasc Pharmacol; 2023; 21(2):106-110. PubMed ID: 36918781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
    Martin N; Manoharan K; Thomas J; Davies C; Lumbers RT
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD012721. PubMed ID: 29952095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mineralocorticoid Receptor Antagonists and Renal Outcomes in Heart Failure Patients with and without Chronic Kidney Disease.
    Mavrakanas TA; Giannetti N; Sapir-Pichhadze R; Alam A
    Cardiorenal Med; 2020; 10(1):32-41. PubMed ID: 31665724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities.
    Albert NM; Tyson RJ; Hill CL; DeVore AD; Spertus JA; Duffy C; Butler J; Patterson JH; Hernandez AF; Williams FB; Thomas L; Fonarow GC
    Am Heart J; 2021 May; 235():82-96. PubMed ID: 33497697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.